Estimation of mRNA-1283 vs BNT162b2 COVID-19 Vaccine Effectiveness in Older US Veterans

In this cohort study of older US veterans during the 2025-2026 respiratory virus season, mRNA-1283 vaccination was associated with lower risks of medically attended COVID-19 outcomes and COVID-19 hospitalizations compared with BNT162b2 vaccination. The findings suggest that the mRNA-1283 vaccine may offer more clinically meaningful protection for older adults at high risk of severe COVID-19 outcomes and could inform seasonal vaccine selection.

Corresponding Author: Kevin W. McConeghy, PharmD, PhD, Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation, Veterans Affairs (VA) Providence Healthcare System, 830 Chalkstone Ave, Providence, RI 02908 (kevin_mcconeghy@brown.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.